Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Acalabrutinib and Rituximab in Untreated Elderly and/or Frail Patients With DLBCL
NCT05952024Phase 2Recruiting
- Sponsor
- AstraZeneca
- Start
- Jul 2024
- Primary completion
- Apr 2029
- Countries
- 5
01
Overview
Phase 2, open-label, single-arm trial of acalabrutinib tablet (Variant 1) in diffuse large B-cell lymphoma (DLBCL), sponsored by AstraZeneca. Primary endpoint: Percentage of patients with Grade 3 to 4 treatment emergent adverse events up to 3.5 Years. Started Jul 2024; status: recruiting.
02
Drugs
acalabrutinib tablet (Variant 1)
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT05952024.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05952024.